

**HB 2879 Advisory Committee Meeting
October 13, 2015 1:30-3:30pm
Board of Pharmacy; 800 NE Oregon Street Portland 97232**

Minutes

ATTENDEES

- | | |
|--|--|
| <input type="checkbox"/> Emily Elman | <input type="checkbox"/> Fiona Karbowicz |
| <input type="checkbox"/> Helene Rimberg | <input type="checkbox"/> Gary Miner |
| <input type="checkbox"/> Lorinda Anderson | <input type="checkbox"/> Nicole Krishnaswami (phone) |
| <input type="checkbox"/> Christy Cowgill | <input type="checkbox"/> Crystal Bryan (phone) |
| <input type="checkbox"/> Doan Pham, BOP Intern | <input type="checkbox"/> |

Unable to Attend: Dr. Pete Palacio, Dr. Maria Rodriguez, Sarah Wickenhagen, Dr. Carrie Miles, Marc Watt

Agenda Item	Desired Outcome
Welcome	Introductions
Review of 10.13.2015 Meeting	<ul style="list-style-type: none"> ❖ The Committee reviewed and approved draft minutes from 10.13.2015 meeting
Committee Discussions	<ul style="list-style-type: none"> ❖ The Committee reviewed final drafts of the Oregon Self-Screening Risk Assessment Questionnaire and Oregon Standard Procedures Algorithm to address changes suggested by the Board at the 10.8.2015 meeting. <ul style="list-style-type: none"> ▪ An asterisk was added to the 'Age' line at the top of the Questionnaire as a reminder to confirm DOB with valid photo ID <i>and</i> as a reminder for the bill mandates for prescribing to patients under the age of 18. ▪ For record-keeping purposes, the Questionnaire now contains all the elements to be the valid prescription, with the addition of the sig, pharmacy phone and address lines. A prescription is considered valid pursuant to regulations set forth by OAR 855-041-1105, to include info on the 'front' AND 'back' of a prescription. ▪ The Committee discussed the US MEC related to Questionnaire #s 6 and 7 to address the nuances between post-partum and breastfeeding. The Committee determined that keeping both questions and making the questions as general as possible will provide the pharmacist with the most information for patient evaluation. ▪ The Committee discussed the Algorithm and no changes were made. ❖ The Committee reviewed the Alternate Therapy/Re-Evaluation Questionnaire that may be used by a pharmacist in Algorithm Step 5b for an <i>alteration of therapy</i>. Lorinda explained the differences in pharmacotherapy textbooks to current practice realities related to progesterone activities. <ul style="list-style-type: none"> ▪ Pharmacy textbooks tend to categorize "strong" vs. "weak" progesterone activity but the clinical data do not provide evidence to support this, especially when addressing Breakthrough Bleeding (BTB). ▪ When addressing BTB in clinical practice, it is best to discuss adherence and

smoking, as these are the two primary causes for BTB.

- Fiona and Doan will make edits to the Alternate Therapy Questionnaire to incorporate these clinical components and bring the edits to the Committee for future review. (Recall that this document is not required by rule or Algorithm and will simply be put into the “Toolkit” provided by the Board as a reference document.)
- ❖ The Committee performed a detailed review of the draft rules, now codified as OAR 855-019-0400 through 0435.
 - The Committee confirmed the Board’s edits made at their 10.8.2015 meeting, with a few exceptions:
 - “Clinical Visit” was re-defined, as related to these rules.
 - The Committee made slight re-structuring to the Procedural Mandates rule (19-0425) for clarification.
 - The Committee discussed the Visit Summary rule requirements and determined that while this is a critical document to be provided to each patient, it is not necessary to require the pharmacy to retain it in records. A pharmacy may choose to keep a copy of what the pharmacist gave to the patient, but the Committee stated that all reasons to refer are recorded on the Questionnaire/prescription.
- ❖ The Committee did not have time to discuss additional Appendices.